SLC5A2 and metabolic dysfunction-associated steatohepatitis: In addition, by reducing fat mass, SGLT2 inhibitors prevent the adipocyte release of inflammatory cytokines, thus reducing the inflammatory effects, which are a major cause of MASH progression [171].